<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615691</url>
  </required_header>
  <id_info>
    <org_study_id>261203</org_study_id>
    <secondary_id>2015-002136-40</secondary_id>
    <nct_id>NCT02615691</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) &lt; 6 Years of Age With Severe Hemophilia A</brief_title>
  <official_title>Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) &lt; 6 Years With Severe Hemophilia A (FVIII &lt; 1%)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate safety, immunogenicity and hemostatic efficacy of
      PEGylated recombinant FVIII (BAX 855) in previously untreated patients (PUPs) &lt; 6 years of
      age with severe hemophilia A (baseline FVIII level &lt; 1%) and &lt; 3 EDs to ADVATE, BAX 855 or
      plasma transfusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2015</start_date>
  <completion_date type="Anticipated">June 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of FVIII inhibitor development</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Success rate of Immune tolerance induction (ITI)</measure>
    <time_frame>Up to 33 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Binding Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
    <description>Binding IgG and IgM antibodies to Factor VIII (FVIII), Factor VIII-Polyethylene glycol (PEG-FVIII) and Polyethylene glycol (PEG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Throughout Part A and Part B of the study, approximately 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>Throughout Part A and Part B of the study, approximately 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in clinical laboratory parameters</measure>
    <time_frame>Throughout Part A and Part B of the study, approximately 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) for prophylactic and on-demand treatment</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of BAX 855 infusions per bleeding episode</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall hemostatic efficacy rating</measure>
    <time_frame>24 h after initiation of treatment and at resolution of bleed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-adjusted consumption of BAX 855 per month, per year and per event</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions per month and per year</measure>
    <time_frame>Throughout Part A of the study, approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of intra-, post- and perioperative hemostatic efficacy in case of surgery</measure>
    <time_frame>Surgery Day 0 up to postoperative Day 14 or discharge (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra- and postoperative blood loss in case of surgery</measure>
    <time_frame>Surgery Day 0 up to postoperative Day 14 or discharge (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Incremental recovery (IR) at baseline and over time</measure>
    <time_frame>Pre-infusion within 30 minutes; and post-infusion at 15-30 minutes and 24-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- Half-life (T1/2) at baseline (optional)</measure>
    <time_frame>Post-infusion: 15-30 minutes and 24-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - Rate of partial success and failure of ITI</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - annualized bleeding rate (ABR) during ITI</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - Weight-adjusted consumption of BAX 855 per month and per year for each ITI regimen employed</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) - Catheter-related complications</measure>
    <time_frame>Up to 33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune tolerance induction (ITI) -Binding Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies</measure>
    <time_frame>Up to 33 months</time_frame>
    <description>Binding IgG and IgM antibodies to Factor VIII (FVIII), Factor VIII-Polyethylene glycol (PEG-FVIII) and Polyethylene glycol (PEG)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Previously untreated patients (PUPs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;6 years of age with severe hemophilia A (baseline Factor VIII (FVIII) level &lt; 1%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGylated Recombinant Factor VIII</intervention_name>
    <description>Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)</description>
    <arm_group_label>Previously untreated patients (PUPs)</arm_group_label>
    <other_name>ADYNOVATE</other_name>
    <other_name>BAX855</other_name>
    <other_name>BAX 855</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Participant is &lt; 6 years old at the time of screening

          2. Participant is previously untreated with &lt; 3 exposure days (EDs) to ADVATE, BAX 855 or
             plasma transfusion at any time prior to screening

          3. Participant has severe hemophilia A (Factor VIII (FVIII) &lt; 1%) as determined by the
             central laboratory, or a historical FVIII level &lt; 1% as determined at any local
             laboratory, optionally supported by an additional FVIII gene mutation consistent with
             severe hemophilia A

          4. Participant is immune competent with a CD4+ count &gt; 200 cells/mm^3, as confirmed by
             the central laboratory at screening

          5. Parent or legally authorized representative is willing and able to comply with the
             requirements of the protocol

        Additional inclusion criteria for Part B (immune tolerance induction (ITI))

          1. Parent or legal representative has/have voluntarily provided signed informed consent
             for ITI portion

          2. Participant has a confirmed positive high titer inhibitor (&gt; 5.00 Bethesda unit (BU))
             or has a positive confirmed low titer inhibitor (≥ 0.6 BU) as determined by the
             central laboratory based on a second repeat blood sample with

               1. poorly controlled bleeding despite increased BAX 855 doses, or

               2. requires bypassing agents to treat bleeding

        Exclusion Criteria

          1. Participant has detectable FVIII inhibitory antibodies (≥ 0.6 BU using the Nijmegen
             modification of the Bethesda assay) as confirmed by central laboratory at screening

          2. Participant has a history of FVIII inhibitory antibodies (≥ 0.6 BU using the Nijmegen
             modification of the Bethesda assay or the Bethesda assay) at any time prior to
             screening

          3. Participant has been diagnosed with an inherited or acquired hemostatic defect other
             than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease)

          4. Participant has been previously treated with any type of FVIII concentrate other than
             ADVATE or BAX 855, or was administered ADVATE, BAX 855 or plasma transfusion for ≥ 3
             EDs at any time prior to screening

          5. Participant receives &gt;2 EDs of ADVATE in total during the periods prior to enrollment
             and during the screening period, until the baseline infusion.

          6. The participant's weight is anticipated to be &lt; 5 kg at the baseline visit

          7. Participant's platelet count is &lt; 100,000/mL

          8. Participant has known hypersensitivity towards mouse or hamster proteins, polyethylene
             glycol (PEG) or Tween 80

          9. Participant has severe chronic hepatic dysfunction [eg, &gt; 5 times upper limit of
             normal alanine aminotransferase (ALT), aspartate aminotransferase (AST), or a
             documented international normalized ratio (INR) &gt; 1.5] in his medical history or at
             the time of screening

         10. Participant has severe renal impairment (serum creatinine &gt; 1.5 times the upper limit
             of normal)

         11. Participant has current or recent (&lt; 30 days) use of other PEGylated drugs prior to
             study participation or is scheduled to use such drugs during study participation

         12. Participant is scheduled to receive during the course of the study a systemic
             immunomodulating drug (e.g. corticosteroid agents at a dose equivalent to
             hydrocortisone greater than 10 mg/day or α-interferon) other than anti-retroviral
             chemotherapy

         13. Participant has participated in another clinical study involving an investigational
             product (IP) or investigational device within 30 days prior to enrollment or is
             scheduled to participate in another clinical study involving an IP or investigational
             device during the course of this study

         14. Parent or legally authorized representative has a medical, psychiatric, or cognitive
             illness or recreational drug/alcohol use that, in the opinion of the investigator,
             would affect participant safety or compliance

         15. Parent, legally authorized representative or participant are a member of the team
             conducting this study or is in a dependent relationship with one of the study team
             members. Dependent relationships include close relatives (ie, children,
             partner/spouse, siblings, parents) as well as employees of the investigator or site
             personnel conducting the study.

        Additional exclusion criteria for Part B (ITI)

          1. Spontaneous disappearance of the inhibitor prior to ITI

          2. FVIII inhibitor titer ≥ 0.6 BU is not confirmed by a second new blood sample and
             determined at the central laboratory

          3. Inability or unwillingness to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine Knoll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland M.C.</name>
      <address>
        <city>Cupertino</city>
        <state>California</state>
        <zip>95014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Laura Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland M.C.</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Laura Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland M.C.</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Laura Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Ducore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Med Ctr</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Donna Boruchov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ Florida College Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tung Wynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Sidonio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's H</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexis Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bleeding and Clotting Dis.Inst.</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Tarantino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHS</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela Weyand</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine McGuinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paulette Bryant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natalia Dixon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Mullins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies/Childrens Htl</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Ahuja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State MS Hershey Med Ctr</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elaine Eyster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lisa Hartman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rosa Diaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Meznarich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Le Phu-Quoc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Uni Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Van Damme An</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. Ziekenhuis Gent Apotheek</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veerle Mondelaers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veerle Labarque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Georgi, EAD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Spasova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SHAT Oncohaematology Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dobrin Konstantinov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT Sv. Marina, EAD</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valeria Kaleva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaye Edmonton Clinic</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Belletrutti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster Health Science</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marianne Hoffmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki Univ Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Satu Langstrom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU CAEN Hopital Cote de Nacre</name>
      <address>
        <city>Caen cedex 9</city>
        <state>Calvados</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Essais cliniques CHU Rennes</name>
      <address>
        <city>Rennes cedex 09</city>
        <state>Ille Et Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Bayart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris cedex 15</city>
        <state>Paris</state>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annie Harroche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne de Flandre - CHU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Susen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>ROUEN Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pascale Schneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Werlhof-Institut GmbH</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cornelia Wermes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inst. f. Experimentelle</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Goldmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik F.Haematologie,Onkologie</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Juergen Laws</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poliklinik PaediaHaematologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johanna Schrum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Godfrey Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese University Of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chi Kong LI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belgyogyaszat Onkohaematologia</name>
      <address>
        <city>Budapest</city>
        <zip>1086</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marianna Zombori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem</name>
      <address>
        <city>Debrece</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Csongor Kiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero F. Alessi</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giuffrida Gaetano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giancarlo Castaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Flora Peyvandi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umberto I Pol. di Roma-Università di Roma La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Chistolini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>You Chur Woo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lyu Chuhl Joo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Young Shil Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang Kyu Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang</city>
        <state>Kuala Lumpur</state>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jameela Sathar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital HRPB</name>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aisyah Muhammad Rivai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Georgetown</city>
        <state>Pulau Pinang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seoh Leng Yeoh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hishamshah Mohd Ibrahim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gek Bee Ong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Nur Zahirah</name>
      <address>
        <city>Terengganu</city>
        <zip>20400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nazzlin Dizana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rienk Tamminga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus - Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>N-0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Heidi Glosli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NUS YLL School of Medicine</name>
      <address>
        <city>Singapore</city>
        <zip>117599</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pei Lin KOH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KKH</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joyce Lam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
    </contact>
    <investigator>
      <last_name>Mariana Isabel Canaro Hirnyk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HOSPITAL A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Fernanda Lopez Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Teresa Alvarez Roman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univ del Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Garcia Frade</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chung- Ho Memorial Hosp</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chiou Shyh-Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ching-Tien Peng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiaan-Der Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yeu-Chin Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pongtanakul Bunchoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial</name>
      <address>
        <city>Patumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sosothikul Darintr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chuansumrit Ampaiwan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natesirinilkul Rungrote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Muang</city>
        <state>Khon Kaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Komvilaisak Patcharee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital</name>
      <address>
        <city>Adana</city>
        <zip>1130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ali Bulent Antmen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe Üniversitesi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Selin Aytac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi</name>
      <address>
        <city>Antalya</city>
        <zip>7058</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Osman Alphan Kupesiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uludag Universitesi Tip Fakültesi</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adalet Meral Gunes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istanbul Üniversitesi Cerrahpaşa</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bulent Zulfikar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kaan Kavakli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erciyes Univers Tip Fakultesi</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekrem Unal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>19 Mayis Universitesi</name>
      <address>
        <city>Samsun</city>
        <zip>55319</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Canan Albayrak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MI Cherkasy Reg Onc Dis of CRC</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Viktor Paramonov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SI Institute of Blood Pathology and Transfusion Medicine of NAMSU</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oleksandra Stashyshyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia Reg CCH of ZRC</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrii Borodin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Grainger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rashid Kazmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal H. for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emma Phillips</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelina Children's Hospital - St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jayanthi Alamelu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
    <mesh_term>BAX 855</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

